Passed by the House January 26, 2022 Yeas 97 Nays 0 LAURIE JINKINS
Speaker of the House of Representatives Passed by the Senate March 1, 2022 Yeas 48 Nays 0 DENNY HECK
President of the Senate | CERTIFICATE I, Bernard Dean, Chief Clerk of the House of Representatives of the State of Washington, do hereby certify that the attached is SUBSTITUTE HOUSE BILL 1675 as passed by the House of Representatives and the Senate on the dates hereon set forth. BERNARD DEAN
Chief Clerk Chief Clerk |
Approved March 11, 2022 10:19 AM | FILED March 11, 2022 |
JAY INSLEE
Governor of the State of Washington | Secretary of State State of Washington |
SUBSTITUTE HOUSE BILL 1675
Passed Legislature - 2022 Regular Session
State of Washington | 67th Legislature | 2022 Regular Session |
ByHouse Health Care & Wellness (originally sponsored by Representatives Bateman, Maycumber, Leavitt, Graham, Dolan, Cody, Griffey, and Riccelli)
READ FIRST TIME 01/20/22.
AN ACT Relating to exempting a manufacturer of certain dialysate and dialysis devices used by home dialysis patients or a manufacturer's agent from the pharmacy practices act and legend drug act; and amending RCW
18.64.257 and
69.41.032.
BE IT ENACTED BY THE LEGISLATURE OF THE STATE OF WASHINGTON:
Sec. 1. RCW
18.64.257 and 2013 c 19 s 20 are each amended to read as follows:
(1) This chapter shall not prevent a medicare-approved dialysis center ((
or))
, a facility operating a medicare-approved home dialysis program
, a manufacturer, or a wholesaler, from selling, delivering, possessing, or dispensing directly to its dialysis patients, ((
in case or full shelf lots,)) if prescribed by a ((
physician licensed under chapter 18.57 or 18.71 RCW))
practitioner acting within the scope of the practitioner's practice, those
dialysis devices and legend drugs
, including commercially available dialysate, used by home dialysis patients, in case or full shelf lots, as determined by the commission ((
pursuant to rule)).
(2) The commission shall adopt rules to implement this section.
Sec. 2. RCW
69.41.032 and 2016 c 148 s 12 are each amended to read as follows:
(1) This chapter shall not prevent a medicare-approved dialysis center ((
or))
, a facility operating a medicare-approved home dialysis program
, a manufacturer, or a wholesaler, from selling, delivering, possessing, or dispensing directly to ((
its)) dialysis patients, ((
in case or full shelf lots,)) if prescribed by a ((
physician licensed under chapter 18.57 or 18.71 RCW))
practitioner acting within the scope of the practitioner's practice, those legend drugs
, including commercially available dialysate, used by home dialysis patients, in case or full shelf lots, as determined by the commission ((
pursuant to rule)).
(2) The commission shall adopt rules to implement this section.
Passed by the House January 26, 2022.
Passed by the Senate March 1, 2022.
Approved by the Governor March 11, 2022.
Filed in Office of Secretary of State March 11, 2022.
--- END ---